📊 AVTX Key Takeaways
Is Avalo Therapeutics, Inc. (AVTX) a Good Investment?
Avalo Therapeutics is a pre-revenue pharmaceutical company burning $17.8M annually with only $59K in revenue, providing a cash runway of approximately 16-17 months at current burn rates. The company exhibits severe unprofitability (net margin of -33,271%) and cannot cover interest expenses from operations, indicating it will require substantial capital raises or immediate commercial success to survive. Despite a moderately strong balance sheet today, the fundamental financial trajectory is unsustainable.
Avalo Therapeutics shows the classic profile of a highly speculative, pre-revenue biotech with no operating revenue, deeply negative operating and net income, and materially negative free cash flow. While the balance sheet is not heavily levered and near-term liquidity ratios look strong, the absolute cash balance appears limited relative to ongoing cash burn, making future dilution or financing risk a central fundamental concern.
Avalo Therapeutics, Inc. Key Strengths (AVTX)
- Substantial liquidity cushion with $25.0M cash reserves and 7.66x current ratio reducing near-term insolvency risk
- Conservative leverage with 0.21x Debt/Equity ratio limiting financial distress impact
- Positive year-over-year improvement in diluted EPS (-0.98 vs prior -1.71, +72.1% improvement indicating operational progress)
- Low balance-sheet leverage with debt/equity of 0.16x limits financial strain versus heavily indebted peers
- High current and quick ratios indicate minimal near-term liability pressure
- Positive YoY EPS improvement suggests some loss-per-share compression, likely helped by capital structure changes or cost control
AVTX Stock Risks: Avalo Therapeutics, Inc. Investment Risks
- Critical cash burn of $17.8M annually with only 16-17 months of runway before capital requirement becomes acute
- Revenue collapse of 86.6% YoY with current revenue of $59K indicating no commercial traction or market validation
- Negative interest coverage (-32.9x) means company cannot service debt from operations, forcing reliance on asset liquidation or dilutive financing
- Binary pharmaceutical development risk: company will face extinction or massive dilution unless clinical programs achieve approval and revenue
- Zero revenue and sharply declining top line indicate no commercial base to support operations
- Large operating and free cash flow losses point to weak profitability quality and ongoing cash consumption
- Cash of $26.96M appears thin relative to negative operating cash flow of $37.21M, raising funding and dilution risk
Key Metrics to Watch
- Monthly cash burn trend and exact runway months remaining before forced capital raise
- Clinical program milestones and safety/efficacy data from ongoing trials
- Revenue and licensing deal announcements indicating commercialization path or partnerships
- Terms and dilution percentage of any capital raises or debt restructuring
- Quarterly operating cash burn versus cash and equivalents
- Clinical/regulatory progress that can translate into sustainable revenue generation
Avalo Therapeutics, Inc. (AVTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.66x current ratio provides a solid financial cushion.
AVTX Profit Margin, ROE & Profitability Analysis
AVTX vs Healthcare Sector: How Avalo Therapeutics, Inc. Compares
How Avalo Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Avalo Therapeutics, Inc. Stock Overvalued? AVTX Valuation Analysis 2026
Based on fundamental analysis, Avalo Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Avalo Therapeutics, Inc. Balance Sheet: AVTX Debt, Cash & Liquidity
AVTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Avalo Therapeutics, Inc.'s revenue has declined by 93% over the 5-year period, indicating business contraction. The most recent EPS of $-20.91 indicates the company is currently unprofitable.
AVTX Revenue Growth, EPS Growth & YoY Performance
AVTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $210.0K | $-2.19 |
| Q3 2024 | $236.0K | $210.0K | $-2.83 |
| Q2 2024 | N/A | -$8.2M | $-14.07 |
| Q1 2024 | N/A | -$10.0M | $-141.00 |
| Q3 2023 | $236.0K | $3.2M | $-0.11 |
| Q2 2023 | $643.0K | -$8.2M | $-0.59 |
| Q1 2023 | $475.0K | -$10.0M | $-0.85 |
| Q3 2022 | $1.4M | $3.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Avalo Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
AVTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Avalo Therapeutics, Inc. (CIK: 0001534120)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AVTX
What is the AI rating for AVTX?
Avalo Therapeutics, Inc. (AVTX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AVTX's key strengths?
Claude: Substantial liquidity cushion with $25.0M cash reserves and 7.66x current ratio reducing near-term insolvency risk. Conservative leverage with 0.21x Debt/Equity ratio limiting financial distress impact. ChatGPT: Low balance-sheet leverage with debt/equity of 0.16x limits financial strain versus heavily indebted peers. High current and quick ratios indicate minimal near-term liability pressure.
What are the risks of investing in AVTX?
Claude: Critical cash burn of $17.8M annually with only 16-17 months of runway before capital requirement becomes acute. Revenue collapse of 86.6% YoY with current revenue of $59K indicating no commercial traction or market validation. ChatGPT: Zero revenue and sharply declining top line indicate no commercial base to support operations. Large operating and free cash flow losses point to weak profitability quality and ongoing cash consumption.
What is AVTX's revenue and growth?
Avalo Therapeutics, Inc. reported revenue of $59.0K.
Does AVTX pay dividends?
Avalo Therapeutics, Inc. does not currently pay dividends.
Where can I find AVTX SEC filings?
Official SEC filings for Avalo Therapeutics, Inc. (CIK: 0001534120) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AVTX's EPS?
Avalo Therapeutics, Inc. has a diluted EPS of $-0.98.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AVTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Avalo Therapeutics, Inc. has a D grade with 80% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AVTX stock overvalued or undervalued?
Valuation metrics for AVTX: ROE of -28.7% (sector avg: 15%), net margin of -33,271.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AVTX's AI grade for 2026?
Our dual AI analysis gives Avalo Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AVTX's free cash flow?
Avalo Therapeutics, Inc.'s operating cash flow is $-17.7M, with capital expenditures of $95.0K. FCF margin is -30,145.8%.
How does AVTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -33,271.2% (avg: 12%), ROE -28.7% (avg: 15%), current ratio 7.66 (avg: 2).